![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Biosyent Inc | TSXV:RX | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.39 | 3.82% | 10.60 | 10.58 | 11.00 | 11.45 | 10.00 | 10.39 | 46,330 | 21:12:16 |
“Our access to healthcare professionals improved during Q2 2022 as our expanded field salesforce had more opportunities for in-person engagement with these professionals during the quarter than since the outset of the COVID-19 pandemic in March 2020,” commented Mr. René Goehrum, President and CEO of BioSyent. “This improved access benefited our launch brands, Tibella® and Combogesic® in particular, which both posted double-digit unit sales growth during the quarter. Overall, our Canadian pharmaceutical sales from continuing brands grew marginally during the quarter (excluding the discontinued Aguettant System® and Cysview® brands), with some inventory rebalancing at the wholesale level for certain products in the comparative quarter. Q2 2022 marked BioSyent’s 48th consecutive profitable quarter with a healthy net profit margin of 18%, improving from the comparative period on changes in product mix as well as certain non-recurring launch-related promotional expenditures incurred in Q2 2021. Our track record of growth and 12 consecutive years of profitability gives us confidence in our ability to return capital to shareholders.”
The CEO’s presentation on the Q2 2022 Results is available at the following link: www.biosyent.com/q2-22/.
The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and six months ended June 30, 2022 and 2021 will be posted on www.sedar.com on August 23, 2022.
BioSyent further announces that its Board of Directors has approved a grant of 1,813 Restricted Share Units “RSUs” to certain employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years of the applicable grant date.
For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
As of the date of this press release, the Company has 12,213,111 common shares outstanding.
BioSyent Inc. | ||||||||||||
Interim Unaudited Condensed Consolidated Statements of Net Income and Comprehensive Income | ||||||||||||
In Canadian Dollars | Q2 2022 | Q2 2021 | % Change | H1 2022 | H1 2021 | % Change | ||||||
Net Revenues | 6,634,875 | 7,289,254 | -9% | 13,672,286 | 14,709,143 | -7% | ||||||
Cost of Goods Sold | 1,170,804 | 1,586,168 | -26% | 2,617,460 | 3,150,062 | -17% | ||||||
Gross Profit | 5,464,071 | 5,703,086 | -4% | 11,054,826 | 11,559,081 | -4% | ||||||
Operating Expenses and Finance Income/Costs | 3,814,940 | 4,324,515 | -12% | 7,255,520 | 7,926,796 | -8% | ||||||
Net Income Before Tax | 1,649,131 | 1,378,571 | 20% | 3,799,306 | 3,632,285 | 5% | ||||||
Tax (including Deferred Tax) | 431,248 | 360,497 | 20% | 993,519 | 949,843 | 5% | ||||||
Net Income After Tax | 1,217,883 | 1,018,074 | 20% | 2,805,787 | 2,682,442 | 5% | ||||||
Net Income After Tax % to Net Revenues | 18% | 14% | 21% | 18% | ||||||||
EBITDA | 1,688,583 | 1,491,783 | 13% | 3,915,945 | 3,850,868 | 2% | ||||||
EBITDA % to Net Revenues | 25% | 20% | 29% | 26% |
BioSyent Inc. | ||||||
Interim Unaudited Condensed Consolidated Statements of Financial Position | ||||||
AS AT | June 30, 2022 | December 31, 2021 | % Change | |||
ASSETS | ||||||
Cash, cash equivalents and short-term investments | $ | 27,898,550 | $ | 28,211,670 | -1 | % |
Income tax recoverable | 78,067 | - | 100 | % | ||
Trade and other receivables | 3,347,572 | 2,787,305 | 20 | % | ||
Inventory | 2,775,473 | 2,204,331 | 26 | % | ||
Prepaid expenses and deposits | 563,785 | 456,034 | 24 | % | ||
Loans receivable - current | 64,869 | 420,104 | 100 | % | ||
CURRENT ASSETS | 34,728,316 | 34,079,444 | 2 | % | ||
Property and equipment | 1,804,937 | 1,931,569 | -7 | % | ||
Intangible assets | 950,759 | 874,026 | 9 | % | ||
Loans receivable - non current | 347,677 | 183,201 | 90 | % | ||
Deferred tax asset | 148,066 | 99,216 | 49 | % | ||
TOTAL NON CURRENT ASSETS | 3,251,439 | 3,088,012 | 5 | % | ||
TOTAL ASSETS | $ | 37,979,755 | $ | 37,167,456 | 2 | % |
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES | $ | 3,737,352 | $ | 4,137,266 | -10 | % |
NON CURRENT LIABILITIES | 1,515,163 | 1,475,264 | 3 | % | ||
Long term debt | - | - | 0 | % | ||
Total Equity | 32,727,240 | 31,554,926 | 4 | % | ||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 37,979,755 | $ | 37,167,456 | 2 | % |
For further information please contact:Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web: www.biosyent.com
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
1 Year Biosyent Chart |
1 Month Biosyent Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions